Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Zentalis Pharmaceuticals ...

    NASDAQ: ZNTL · Real-Time Price · USD
    1.50
    0.16 (11.94%)
    At close: Jun 16, 2025, 3:59 PM
    1.55
    3.33%
    After-hours: Jun 16, 2025, 07:49 PM EDT

    Zentalis Pharmaceuticals Statistics

    Share Statistics

    Zentalis Pharmaceuticals has 71.95M shares outstanding. The number of shares has increased by 1.12% in one year.

    Shares Outstanding

    n/a
    		 71.95M

    Shares Change (YoY)

    n/a
    		 1.12%

    Shares Change (QoQ)

    n/a
    		 0.77%

    Owned by Institutions (%)

    n/a
    		 90.59%

    Shares Floating

    n/a
    		 55.8M

    Failed to Deliver (FTD) Shares

    n/a
    		 400

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 5.88M, so 8.17% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.88M

    Short % of Shares Out

    n/a
    		 8.17%

    Short % of Float

    n/a
    		 10.2%

    Short Ratio (days to cover)

    n/a
    		 9.08

    Valuation Ratios

    The PE ratio is -1.3 and the forward PE ratio is -0.68. Zentalis Pharmaceuticals's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -1.3

    Forward PE

    n/a
    		 -0.68

    PS Ratio

    n/a
    		 3.19

    Forward PS

    n/a
    		 0.6

    PB Ratio

    n/a
    		 0.64

    P/FCF Ratio

    n/a
    		 -1.26

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.32, with a Debt / Equity ratio of 0.12.

    Current Ratio

    n/a
    		 7.32

    Quick Ratio

    n/a
    		 7.32

    Debt / Equity

    n/a
    		 0.12

    Debt / EBITDA

    n/a
    		 -0.21

    Debt / FCF

    n/a
    		 -0.23

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $406,174.7

    Profits Per Employee

    n/a
    		 $-999,030.12

    Employee Count

    n/a
    		 166

    Asset Turnover

    n/a
    		 0.16

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 177K

    Effective Tax Rate

    n/a
    		 -0.11%

    Stock Price Statistics

    The stock price has increased by -82.12% in the last 52 weeks. The beta is 1.61, so Zentalis Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.61

    52-Week Price Change

    n/a
    		 -82.12%

    50-Day Moving Average

    n/a
    		 1.32

    200-Day Moving Average

    n/a
    		 2.46

    Relative Strength Index (RSI)

    n/a
    		 56.57

    Average Volume (20 Days)

    n/a
    		 835,171

    Income Statement

    In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.

    Revenue

    n/a
    		 67.42M

    Gross Profit

    n/a
    		 67.42M

    Operating Income

    n/a
    		 -191.19M

    Net Income

    n/a
    		 -165.84M

    EBITDA

    n/a
    		 -191.19M

    EBIT

    n/a
    		 -187.46M

    Earnings Per Share (EPS)

    n/a
    		 -2.33
    Full Income Statement

    Balance Sheet

    The company has 33.9M in cash and 39.58M in debt, giving a net cash position of -5.68M.

    Cash & Cash Equivalents

    n/a
    		 33.9M

    Total Debt

    n/a
    		 39.58M

    Net Cash

    n/a
    		 -5.68M

    Retained Earnings

    n/a
    		 -1.05B

    Total Assets

    n/a
    		 384.02M

    Working Capital

    n/a
    		 293.45M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -170.86M and capital expenditures -221K, giving a free cash flow of -171.08M.

    Operating Cash Flow

    n/a
    		 -170.86M

    Capital Expenditures

    n/a
    		 -221K

    Free Cash Flow

    n/a
    		 -171.08M

    FCF Per Share

    n/a
    		 -2.41
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -283.57% and -245.96%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -283.57%

    Pretax Margin

    n/a
    		 -245.74%

    Profit Margin

    n/a
    		 -245.96%

    EBITDA Margin

    n/a
    		 -283.57%

    EBIT Margin

    n/a
    		 -283.57%

    FCF Margin

    n/a
    		 -253.74%

    Dividends & Yields

    ZNTL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ZNTL is $8, which is 433.3% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 433.3%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.22

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist